An observational study suggests coprescription of Phosphodiesterase Type 5 Inhibitors (i.e., sildenafil) and oral Nitrates is not associated with increased risk of adverse cardiovascular outcomes in male patients with ischemic heart disease.

Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease: A Case-Crossover Study – Annals of Internal Medicine

Commentaries:

PDE5 inhibitors didn’t increase cardiovascular events in men on nitrates for heart disease – ACP Internist

PDE5 Inhibitors Prescribed for Men on Oral Nitrates for IHD – HealthDay